Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245094 | 1.00 | PTGS2 (0.38) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4022899 | 0.93 | PTGS2 (0.35) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4026915 | 0.91 | MAPT (0.38) | ALDH1A1MAPTHTTKMT2AMEN1 | |
| SCHEMBL4026913 | 0.91 | MAPT (0.38) | ALDH1A1MAPTHTTKMT2AMEN1 | |
| SCHEMBL1448519 | 0.89 | ALDH1A1 (0.40) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL1447709 | 0.89 | ALDH1A1 (0.43) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL1448522 | 0.89 | ALDH1A1 (0.40) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL1447706 | 0.89 | ALDH1A1 (0.43) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4248909 | 0.88 | MAPT (0.45) | PTGS2ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL4248915 | 0.88 | MAPT (0.45) | PTGS2ALDH1A1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | claimed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| EP-2046783-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | ASTRAZENACA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008002245-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188503-A1 | 5-Fluoro-4-[2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl]-N-pyrimidin-5-ylpyrimidin-2-amine; Alzheimer's Disease (AD) Dementias, and Taupathies; GSK3 inhibitors in inflammatory diseases | GSK3B, GSK3A, MAPT | PTGS2 1467/4885ALDH1A1 3227/4885MAPT 3/4885 |
| US-20080188502-A1 | New Compounds I | SLC10A1, REN, SLC5A1 | PTGS2 1220/4885ALDH1A1 363/4885MAPT 2046/4885 |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | PTGS2 4297/4885ALDH1A1 1131/4885MAPT 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.